Trevi Therapeutics Inc (TRVI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -47,911 | -36,496 | -23,254 | -10,902 | -29,065 |
| Depreciation Amortization | 147 | 109 | 73 | 35 | 303 |
| Accounts payable and accrued liabilities | 1,605 | -194 | -324 | 294 | -1,049 |
| Other Working Capital | 6,827 | 5,818 | 2,665 | -62 | -3,847 |
| Other Operating Activity | 1,076 | 2,057 | 1,690 | 168 | 1,948 |
| Operating Cash Flow | $-38,256 | $-28,706 | $-19,150 | $-10,467 | $-31,710 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -35 | -28 | -28 | N/A | -137 |
| Purchase Of Investment | -98,463 | -53,271 | -40,222 | -30,264 | -9,932 |
| Sale Of Investment | 76,970 | 55,643 | 34,927 | 22,173 | 69,497 |
| Investing Cash Flow | $-21,528 | $2,344 | $-5,323 | $-8,091 | $59,428 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -126 | -95 | -63 | -32 | -9,504 |
| Common Stock Issued | 47,464 | 415 | 252 | 4 | 142 |
| Other Financing Activity | 14,146 | 9,697 | 4,850 | 0 | 1,452 |
| Financing Cash Flow | $61,484 | $10,017 | $5,039 | $-28 | $-7,910 |
| Beginning Cash Position | 32,397 | 32,397 | 32,397 | 32,397 | 12,589 |
| End Cash Position | 34,097 | 16,052 | 12,963 | 13,811 | 32,397 |
| Net Cash Flow | $1,700 | $-16,345 | $-19,434 | $-18,586 | $19,808 |
| Free Cash Flow | |||||
| Operating Cash Flow | -38,256 | -28,706 | -19,150 | -10,467 | -31,710 |
| Capital Expenditure | -35 | -28 | -28 | N/A | -137 |
| Free Cash Flow | -38,291 | -28,734 | -19,178 | -10,467 | -31,847 |